KALA BIO
KALA
64 hedge funds and large institutions have $112M invested in KALA BIO in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 9 reducing their positions, and 10 closing their positions.
827% more call options, than puts
Call options by funds: $510K | Put options by funds: $55K
167% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 9
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
8% more funds holding
Funds holding: 59 → 64 (+5)
2.35% more ownership
Funds ownership: 65.61% → 67.96% (+2.4%)
30% less capital invested
Capital invested by funds: $160M → $112M (-$47.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.8M |
| 2 |
ACM
Athyrium Capital Management
New York
|
+$9.26M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$9.07M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.5M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$2.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.13M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$2.65M |
| 3 |
Millennium Management
New York
|
-$1.61M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$797K |
| 5 |
BCP
Berylson Capital Partners
Boston,
Massachusetts
|
-$602K |
KALA Hedge Fund Activity: Q4 2018 in Review
64 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2018, worth a combined $112M — down 30% from $160M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KALA positions and 10 closed out — a net gain of 5 holders — while 24 added to existing stakes and 9 trimmed.
The largest buyer was RA Capital Management, adding an estimated $16.8M. The largest seller was Fidelity Investments, exiting entirely with an estimated $3.13M sold.
- 64 institutional investors held KALA BIO (KALA) as of Q4 2018, up from 59 in Q3 2018.
- Funds reported $112M of KALA BIO stock for Q4 2018, down 30% quarter-over-quarter.
- 15 funds opened new KALA BIO positions in Q4 2018 and 10 closed out, a net change of +5 holders.
- The largest KALA BIO buyer in Q4 2018 was RA Capital Management, an estimated $16.8M added.
- The largest KALA BIO seller in Q4 2018 was Fidelity Investments, an estimated $3.13M sold.
Based on aggregated 13F filings for Q4 2018.